ClinicalTrials.gg
CompletedNCT01642212Updated Jun 8, 2021Results posted

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

A Phase 2 interventional study of Oral Budesonide Suspension (MB-9) and Placebo in Eosinophilic Esophagitis (EoE), sponsored by Shire. Completed at 23 sites in United States. Open to participants aged 11 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
11 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
7th of 18
93 · median 79
Started
2012
with 1 other
Phase 2
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
5 of 18
Shire

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 5th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 11 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)

Read the detailed description

Eosinophilic Esophagitis (EoE) is an inflammatory disorder of the esophagus and is a recognized clinical entity. Symptoms include feeding problems, heartburn, regurgitation, vomiting, abdominal pain and food impaction. The symptoms of EoE may be similar to gastroesophageal reflux disease (GERD) but do not resolve with gastric acid suppression. EoE is defined histologically as the presence of > 15 intraepithelial eosinophils per high power fields on one or more esophageal biopsy specimens.

This Phase II study is comparing oral budesonide (OBS) to placebo to demonstrate that OBS induces a histologic response and a symptom response using a Dysphagia Symptom Questionnaire over a 16 week course of therapy.

03

Conditions studied

  • Eosinophilic Esophagitis (EoE)

Keywords

  • EoE
04

Who can participate

Ages eligible
11 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females, age 11-40
  • Histologic evidence of EoE
  • History of clinical symptoms of EoE including dysphagia
  • Willing to continue with dietary, environmental or medical therapy
  • Ability to read and understand english
  • Written Consent

Exclusion criteria

Exclusion Criteria:

  • Any Medical condition that may compromise the safety of the subjects or interfere with the signs and symptoms of EoE
  • Use of immunomodulatory therapy
  • Current use of swallowed
  • Esophageal strictures,varices or upper GI bleed
  • Other current diseases of the GI tract
  • Current viral infection or immunodeficiency condition
  • Pregnancy
  • to budesonide
  • History of non compliance
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Oral Budesonide Suspension

    Taken once or twice daily for up to 40 weeks

    Drug: Oral Budesonide Suspension (MB-9)

  • Placebo comparator
    Matching Placebo

    Taken once or twice daily for 20 weeks

    Drug: Placebo

Interventions

  • OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percent of Participants Who Were Histologic Responders

    Histologic response was defined as a peak eosinophil count \</= 6/high power field (light microscopy) (HPF) across all esophageal levels at the final treatment evaluation (Week 16). An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.

    Time frame: Week 16

  2. Change From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Change From Baseline in The DSQ Score Over Time

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Weeks 8 and 12

  2. Change From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation

    A cumulative distribution function curve was constructed to illustrate the cumulative proportion of participants (x-axis) vs. the change in the DSQ score from baseline to the final treatment evaluation (y-axis). The 50th percentile is participants with a DSQ score that is in the middle of the distribution of all scores. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Week 16

  3. Percent of Participants With a Peak Eosinophil Count </= 15/High Power Field (Light Microscopy) (HPF) And </= 1/HPF at The Final Treatment Period Evaluation

    An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. The values reported are for participants with histologic response.

    Time frame: Week 16

  4. Percent of Participants With a >/= 30% And >/= 50% Reduction In The DSQ Score From Baseline to The Final Treatment Period Evaluation

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization.

    Time frame: Baseline, Week 16

  5. Percent of Participants Who Were Overall Responders at The Final Treatment Period Evaluation

    Overall response was defined as a reduction in the 2-week DSQ score of \>/= 30% and \>/= 50% from baseline to the final treatment period evaluation and a peak eosinophil count of \</= 6/high power field (light microscopy) (HPF) across all available esophageal levels at the final treatment period evaluation. An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.

    Time frame: Week 16

  6. Change From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation

    Each esophageal biopsy specimen was evaluated microscopically by an independent, central pathologist for signs of epithelial inflammation and lamina propria fibrosis. Histopathologic epithelial features of each available esophageal level biopsy consisting of basal layer hyperplasia, eosinophil peak, dilated intercellular spaces, eosinophil microabcesses, surface layering, surface alteration, and apoptotic epithelial cells were scored and summed. Histopathology data were collected in a blinded fashion. Histopathology epithelial features were scored for both grade and stage. Each feature had a possible score of 0-3 for grade as well as stage. Thus each of the 3 levels had a possible score of 21, and a possible total grade or stage score of 63 for a maximum combined score of 126. The grade and stage score of the lamina propria was not included because the biopsy material was not available. A negative change from baseline indicates that epithelial inflammation decreased.

    Time frame: Baseline, Week 16

  7. Change From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation

    The gross endoscopic appearance of the esophageal surface was evaluated by a blinded study center physician. Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 major categories, including exudates or plaques, fixed esophageal rings, edema, furrows, and strictures. The endoscopy score was the sum of the scores for the 5 major categories - grade 0-1 for strictures; grade 0-2 for exudates or plaques, edema, and furrows; and grade 0-3 for fixed esophageal rings for the proximal and distal locations. The maximum endoscopy score was 10 points for each location (proximal and distal), and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points). Baseline was defined as the endoscopy score at screening. A negative change from baseline indicates that appearance improved.

    Time frame: Baseline, Week 16

  8. Change From Baseline in The Peak Eosinophil Count at Each Available Esophageal Level at The Final Treatment Period Evaluation

    An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. Baseline was defined as the score at screening. A negative change from baseline indicates that eosinophil count decreased.

    Time frame: Baseline, Week 16

  9. Change From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation

    The physician Investigator (or qualified physician's assistant or nurse practitioner) completed the PGA to provide the global assessment of eosinophilic esophagitis (EoE) disease activity using a 0 to 100 mm visual analog scale (VAS) scale. The VAS is a 100 mm horizontal line on which the right extreme (100) is labeled "worst possible disease activity" and the left extreme (0) is labeled "no disease activity". The PGA raters were instructed to consider the line for the VAS a continuum with their own medical opinion or judgment of extremes on either end and to draw a vertical line at a point that best approximates the participant's current level of EoE disease activity. A negative change from baseline indicates that disease activity decreased.

    Time frame: Baseline, Week 16

  10. Distribution of Responses For The Patient Global Impression of Change (PGIC) Survey at The Final Treatment Evaluation

    Participants evaluated the change in their dysphasia (food passing slowly/difficulty swallowing) since the start of the study (screening) by choosing 1 of 7 responses on the PGIC survey: much worse (-3), worse (-2), a little worse (-1), no change (0), a little better (1), better (2), or much better (3). The values reported are the percent of participants who chose that response.

    Time frame: Week 16

  11. Percent of Participants With Improved Symptoms on The Eosinophilic Esophagitis (EoE) Symptom Survey at The Final Treatment Period Evaluation

    The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

    Time frame: Week 16

  12. Percent of Participants With No Change in Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

    The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

    Time frame: Week 16

  13. Percent of Participants With Worsened Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

    The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

    Time frame: Week 16

  14. Percent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

    This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.

    Time frame: Week 16

  15. Percent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

    This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.

    Time frame: Week 16

  16. Percent of Participants Who Were Symptom Responders on The DSQ+Pain Scale at The Final Treatment Period Evaluation

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Question 1 (did you eat solid food) and Question 2 (did food pass slowly or get stuck). If the answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Question 3 (did you have to do anything to make the food go down or get relief) and Question 4 (extent to which the participant experienced pain while swallowing).The DSQ+pain response was defined as a \>/= 30% and \>/= 50% reduction from baseline in the combined score from Questions 2, 3, and 4. The 2-week DSQ+pain score was calculated by adding points from Questions 2, 3, and 4 and then taking the average of the available scores over each 2-week interval.

    Time frame: Week 16

  17. Percent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Values were calculated for all the days that Question 1 was answered from 14 days prior to baseline visit up to the final treatment period evaluation.

    Time frame: From 14 days prior to the baseline visit to the final treatment period evaluation

  18. Change From Baseline in The Scores of DSQ Question 1 During The Treatment Period

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 1 is rated as Yes (score=0) or No (score=1); higher values indicate a worse outcome. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Weeks 8, 12, and 16

  19. Change From Baseline in The Scores of DSQ Question 4 During The Treatment Period

    Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 4 is rated as None, I had no pain (score=0), mild pain (score=1), moderate pain (score=2), severe pain (score=3), or very severe pain (score=4); 4 is the worst pain. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, Weeks 8, 12, and 16

07

Results

Posted Dec 7, 2015

Participant flow

Single-blind Baseline
Participant flow — Single-blind Baseline
MilestoneSingle-blind PlaceboDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgPlacebo to Open-label Oral Budesonide Suspension (OBS) 2 mgOral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg
Started1190000
Completed930000
Not completed260000
Withdrew: Did not meet eligibility criteria260000
Double-blind Treatment
Participant flow — Double-blind Treatment
MilestoneSingle-blind PlaceboDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgPlacebo to Open-label Oral Budesonide Suspension (OBS) 2 mgOral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg
Started0425100
Completed0394900
Not completed03200
Withdrew: Other02100
Withdrew: Non-compliance01000
Withdrew: Adverse event00100
Open-label Extension
Participant flow — Open-label Extension
MilestoneSingle-blind PlaceboDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgPlacebo to Open-label Oral Budesonide Suspension (OBS) 2 mgOral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg
Started0003745
Completed0002737
Not completed000108
Withdrew: Adverse event00030
Withdrew: Sponsor decision00074
Withdrew: Consent withdrawn00002
Withdrew: Lost to follow-up00001
Withdrew: Other00001

Outcome measures

PrimaryPercent of Participants Who Were Histologic Responders

Histologic response was defined as a peak eosinophil count \</= 6/high power field (light microscopy) (HPF) across all esophageal levels at the final treatment evaluation (Week 16). An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants Who Were Histologic Responders
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Percent of Participants Who Were Histologic Responders2.638.8
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Fisher Exact · p = <0.0001
PrimaryChange From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Change From Baseline in The Dysphagia Symptom Questionnaire (DSQ) Score at The Final Treatment Period Evaluation-7.53 ± 1.910-14.27 ± 1.682
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.0096 (LS mean estimates were determined using an ANCOVA model including treatment group as a factor and the baseline score as a covariate.) · Ls mean difference: -6.75 · 95% CI -11.808 to -1.687
SecondaryChange From Baseline in The DSQ Score Over Time

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Weeks 8 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The DSQ Score Over Time
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Week 8, n = 37, 49-4.92 ± 1.673-7.41 ± 1.453
Week 12, n = 36, 49-7.42 ± 2.065-10.33 ± 1.770
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.2649 (LS mean estimates were determined using the ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -2.49 · 95% CI -6.895 to 1.920
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.2878 (LS mean estimates were determined using the ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -2.91 · 95% CI -8.322 to 2.501
SecondaryChange From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation

A cumulative distribution function curve was constructed to illustrate the cumulative proportion of participants (x-axis) vs. the change in the DSQ score from baseline to the final treatment evaluation (y-axis). The 50th percentile is participants with a DSQ score that is in the middle of the distribution of all scores. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Week 16
Reported as:
Number · scores on a scale
Change From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Change From Baseline in The DSQ Score For The 50th Percentile of Participants at The Final Treatment Period Evaluation-6.35-11.20
SecondaryPercent of Participants With a Peak Eosinophil Count </= 15/High Power Field (Light Microscopy) (HPF) And </= 1/HPF at The Final Treatment Period Evaluation

An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. The values reported are for participants with histologic response.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants With a Peak Eosinophil Count </= 15/High Power Field (Light Microscopy) (HPF) And </= 1/HPF at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
</= 15 Eosinophils/HPF7.946.9
</= 1 Eosinophils/HPF030.6
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Fisher Exact · p = 0.0001
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Fisher Exact · p = <0.0001
SecondaryPercent of Participants With a >/= 30% And >/= 50% Reduction In The DSQ Score From Baseline to The Final Treatment Period Evaluation

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing).The DSQ score was calculated based on responses to Questions 2 and 3 \[14 x (sum of points from Questions 2 and 3 in the daily DSQ)/number of diaries with non-missing data\]. Baseline was the DSQ score of the 14-day period before randomization.

Time frame:
Baseline, Week 16
Reported as:
Number · percent of participants
Percent of Participants With a >/= 30% And >/= 50% Reduction In The DSQ Score From Baseline to The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
>/= 30% DSQ Score Reduction44.769.4
>/= 50% DSQ Score Reduction39.563.3
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Pearson's chi-square · p = 0.0206
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Pearson's chi-square · p = 0.0275
SecondaryPercent of Participants Who Were Overall Responders at The Final Treatment Period Evaluation

Overall response was defined as a reduction in the 2-week DSQ score of \>/= 30% and \>/= 50% from baseline to the final treatment period evaluation and a peak eosinophil count of \</= 6/high power field (light microscopy) (HPF) across all available esophageal levels at the final treatment period evaluation. An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value. Histopathology data were collected in a blinded fashion.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants Who Were Overall Responders at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Responder and >/= 30% DSQ Score Reduction2.626.5
Responder and >/= 50% DSQ Score Reduction2.620.4
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Fisher Exact · p = 0.0026
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Fisher Exact · p = 0.0199
SecondaryChange From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation

Each esophageal biopsy specimen was evaluated microscopically by an independent, central pathologist for signs of epithelial inflammation and lamina propria fibrosis. Histopathologic epithelial features of each available esophageal level biopsy consisting of basal layer hyperplasia, eosinophil peak, dilated intercellular spaces, eosinophil microabcesses, surface layering, surface alteration, and apoptotic epithelial cells were scored and summed. Histopathology data were collected in a blinded fashion. Histopathology epithelial features were scored for both grade and stage. Each feature had a possible score of 0-3 for grade as well as stage. Thus each of the 3 levels had a possible score of 21, and a possible total grade or stage score of 63 for a maximum combined score of 126. The grade and stage score of the lamina propria was not included because the biopsy material was not available. A negative change from baseline indicates that epithelial inflammation decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Change From Baseline in The Histopathologic Epithelial Features Combined Total Score at The Final Treatment Period Evaluation-1.41 ± 2.970-23.75 ± 2.602
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = <0.0001 · Ls mean difference: -22.34 · 95% CI -30.345 to -14.334LS mean based on the ANCOVA model including treatment group as a factor and baseline as a covariate.
SecondaryChange From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation

The gross endoscopic appearance of the esophageal surface was evaluated by a blinded study center physician. Endoscopic findings with separate evaluations of the proximal and distal esophagus were recorded with respect to 5 major categories, including exudates or plaques, fixed esophageal rings, edema, furrows, and strictures. The endoscopy score was the sum of the scores for the 5 major categories - grade 0-1 for strictures; grade 0-2 for exudates or plaques, edema, and furrows; and grade 0-3 for fixed esophageal rings for the proximal and distal locations. The maximum endoscopy score was 10 points for each location (proximal and distal), and the total endoscopy score was the sum of the scores for the proximal and distal locations (maximum total score of 20 points). Baseline was defined as the endoscopy score at screening. A negative change from baseline indicates that appearance improved.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Change From Baseline in The Total Endoscopy Score at The Final Treatment Period Evaluation0.19 ± 0.530-3.58 ± 0.466
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = <0.0001 (LS mean estimates based on the ANCOVA model including treatment group as a factor and baseline value as a covariate.) · Ls mean difference: -3.76 · 95% CI -5.172 to -2.358
SecondaryChange From Baseline in The Peak Eosinophil Count at Each Available Esophageal Level at The Final Treatment Period Evaluation

An independent, central pathologist determined the peak eosinophil count from the proximal, mid-, and distal levels and selected the maximum peak value across all available esophagus levels. Histopathology data were collected in a blinded fashion. Baseline was defined as the score at screening. A negative change from baseline indicates that eosinophil count decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · eosinophils/HPF
Change From Baseline in The Peak Eosinophil Count at Each Available Esophageal Level at The Final Treatment Period Evaluation
eosinophils/HPFDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Proximal, n = 32, 45-30.06 ± 6.798-65.56 ± 5.704
Mid-, n = 36, 46-17.34 ± 9.244-76.90 ± 8.173
Distal, n = 38, 49-1.90 ± 9.852-69.28 ± 8.667
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.0002 (LS mean estimates based on the ANCOVA model including treatment group as a factor and baseline value as a covariate.) · Ls mean difference: -35.50 · 95% CI -53.438 to -17.570
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = <0.0001 (LS mean estimates based on the ANCOVA model including treatment group as a factor and baseline value as a covariate.) · Ls mean difference: -59.56 · 95% CI -84.173 to -34.948
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = <0.0001 (LS mean estimates based on the ANCOVA model including treatment group as a factor and baseline value as a covariate.) · Ls mean difference: -67.38 · 95% CI -93.573 to -41.180
SecondaryChange From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation

The physician Investigator (or qualified physician's assistant or nurse practitioner) completed the PGA to provide the global assessment of eosinophilic esophagitis (EoE) disease activity using a 0 to 100 mm visual analog scale (VAS) scale. The VAS is a 100 mm horizontal line on which the right extreme (100) is labeled "worst possible disease activity" and the left extreme (0) is labeled "no disease activity". The PGA raters were instructed to consider the line for the VAS a continuum with their own medical opinion or judgment of extremes on either end and to draw a vertical line at a point that best approximates the participant's current level of EoE disease activity. A negative change from baseline indicates that disease activity decreased.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Change From Baseline in The Physician's Global Assessment (PGA) of Disease Activity at The Final Treatment Period Evaluation-10.16 ± 4.199-28.61 ± 3.695
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.0015 (LS mean estimates were based on the ANCOVA model including treatment group as a factor and baseline value as a covariate.) · Ls mean difference: -18.44 · 95% CI -29.593 to -7.293
SecondaryDistribution of Responses For The Patient Global Impression of Change (PGIC) Survey at The Final Treatment Evaluation

Participants evaluated the change in their dysphasia (food passing slowly/difficulty swallowing) since the start of the study (screening) by choosing 1 of 7 responses on the PGIC survey: much worse (-3), worse (-2), a little worse (-1), no change (0), a little better (1), better (2), or much better (3). The values reported are the percent of participants who chose that response.

Time frame:
Week 16
Reported as:
Number · percent of participants
Distribution of Responses For The Patient Global Impression of Change (PGIC) Survey at The Final Treatment Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Much Worse00
Worse2.62.1
A Little Worse13.22.1
No Change15.812.5
A Little Better28.925.0
Better28.925.0
Much Better10.533.3
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.1170 (P-value for comparison of the treatment difference was determined by Cochran-Mantel-Haenszel row mean score test.)
SecondaryPercent of Participants With Improved Symptoms on The Eosinophilic Esophagitis (EoE) Symptom Survey at The Final Treatment Period Evaluation

The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants With Improved Symptoms on The Eosinophilic Esophagitis (EoE) Symptom Survey at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Heartburn10.518.4
Chest Pain23.718.4
Regurgitation15.820.4
Abdominal Pain15.810.2
Nausea10.516.3
Vomiting5.34.1
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.1947 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.8029 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.4963 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.5257 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.5219 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.2886 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. All responses (improved, no change, worsened) were analyzed collectively for each symptom.)
SecondaryPercent of Participants With No Change in Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants With No Change in Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Heartburn86.871.4
Chest Pain68.471.4
Regurgitation71.173.5
Abdominal Pain76.385.7
Nausea86.877.6
Vomiting81.691.8
SecondaryPercent of Participants With Worsened Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: Improved - participant reported a specific symptom at baseline, but changed to no specific symptom ('Yes' to 'No'); No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report a specific symptom at baseline, but changed to report that specific symptom ('No' to 'Yes').

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants With Worsened Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Heartburn2.610.2
Chest Pain7.910.2
Regurgitation13.26.1
Abdominal Pain7.94.1
Nausea2.66.1
Vomiting13.24.1
SecondaryPercent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Percent of Participants Without Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation71.183.7
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Cochran-Mantel-Haenszel · p = 0.1600 (P-value for comparison of the treatment difference at baseline vs. final treatment evaluation was determined by a Cochran-Mantel-Haenszel row mean score test. Both responses (no change, worsened) were analyzed collectively.)
SecondaryPercent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation

This outcome assessed the symptoms of participants who were symptom-free at baseline. The EoE survey assessed the following symptoms: heartburn, chest pain, regurgitation, abdominal pain, nausea, and vomiting. Participants indicated, by checking a box, if they had a change in symptoms (excluding dysphasia or food impaction) within the past 2 weeks. Baseline was defined as the assessment before randomization. Responses were as follows regarding symptoms at the final treatment evaluation: No change - participant reported or did not report a specific symptom at both baseline and the final treatment evaluation; Worsened -participant did not report any symptom at baseline, but changed to report at least 1 symptom at the final treatment evaluation.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Percent of Participants With New Symptoms on The EoE Symptom Survey at The Final Treatment Period Evaluation28.916.3
SecondaryPercent of Participants Who Were Symptom Responders on The DSQ+Pain Scale at The Final Treatment Period Evaluation

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Question 1 (did you eat solid food) and Question 2 (did food pass slowly or get stuck). If the answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Question 3 (did you have to do anything to make the food go down or get relief) and Question 4 (extent to which the participant experienced pain while swallowing).The DSQ+pain response was defined as a \>/= 30% and \>/= 50% reduction from baseline in the combined score from Questions 2, 3, and 4. The 2-week DSQ+pain score was calculated by adding points from Questions 2, 3, and 4 and then taking the average of the available scores over each 2-week interval.

Time frame:
Week 16
Reported as:
Number · percent of participants
Percent of Participants Who Were Symptom Responders on The DSQ+Pain Scale at The Final Treatment Period Evaluation
percent of participantsDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
>/= 30% DSQ+pain Score Reduction47.467.3
>/= 50% DSQ+pain Score Reduction39.565.3
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Pearson's chi-square · p = 0.0606
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Pearson's chi-square · p = 0.0165
SecondaryPercent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Values were calculated for all the days that Question 1 was answered from 14 days prior to baseline visit up to the final treatment period evaluation.

Time frame:
From 14 days prior to the baseline visit to the final treatment period evaluation
Reported as:
Mean · percentage of days
Percent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods
percentage of daysDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Percent of Days That Participants Reported That They Avoided Solid Food During The Baseline And Treatment Periods1.2 (0.0 to 1.1)0.7 (0.0 to 1.2)
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · Wilcoxon (Mann-Whitney) · p = 0.7817
SecondaryChange From Baseline in The Scores of DSQ Question 1 During The Treatment Period

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 1 is rated as Yes (score=0) or No (score=1); higher values indicate a worse outcome. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Weeks 8, 12, and 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Scores of DSQ Question 1 During The Treatment Period
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Week 8, n = 37, 490.02 ± 0.050-0.08 ± 0.043
Week 12, n = 36, 490.05 ± 0.0910.02 ± 0.078
Week 16, n = 38, 490.05 ± 0.0790.06 ± 0.069
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.1686 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -0.09 · 95% CI -0.222 to 0.040
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.8046 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -0.03 · 95% CI -0.269 to 0.210
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.9239 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: 0.01 · 95% CI -0.199 to 0.219
SecondaryChange From Baseline in The Scores of DSQ Question 4 During The Treatment Period

Participants' dysphagia symptoms were evaluated using the 4-item DSQ. The questionnaire was developed by the Sponsor, as an ePRO measure, according to the principles of the Final Guidance for Industry for Patient Reported Outcome Measures (PRO Guidance December 2009). All participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). Question 4 is rated as None, I had no pain (score=0), mild pain (score=1), moderate pain (score=2), severe pain (score=3), or very severe pain (score=4); 4 is the worst pain. Baseline was the DSQ score of the 14-day period before randomization. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, Weeks 8, 12, and 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in The Scores of DSQ Question 4 During The Treatment Period
scores on a scaleDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mg
Week 8, n = 37, 47-2.52 ± 0.778-3.25 ± 0.690
Week 12, n = 36, 47-2.97 ± 0.775-4.89 ± 0.678
Week 16, n = 38, 47-3.08 ± 0.824-4.87 ± 0.741
Statistical analysis
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.4835 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -0.73 · 95% CI -2.806 to 1.339
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.0662 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -1.92 · 95% CI -3.974 to 0.132
  • Double-blind Placebo vs Double-blind Oral Budesonide Suspension (OBS) 2 mg · ANCOVA · p = 0.1091 (Estimates are determined using an ANCOVA model including treatment group as a factor and baseline DSQ score as a covariate.) · Ls mean difference: -1.80 · 95% CI -4.006 to 0.410

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo—0/42 (0%)21/42 (50%)
Double-blind Oral Budesonide Suspension (OBS) 2 mg—1/51 (2%)20/51 (39.2%)
Placebo to Open-label Oral Budesonide Suspension (OBS) 2 mg—1/37 (2.7%)29/37 (78.4%)
Oral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg—0/45 (0%)27/45 (60%)
Most frequent serious events
Most frequent serious events
EventDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgPlacebo to Open-label Oral Budesonide Suspension (OBS) 2 mgOral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg
Hand FractureInjury, poisoning and procedural complications0/420/511/370/45
Road Traffic AccidentInjury, poisoning and procedural complications0/420/511/370/45
Food poisoningGastrointestinal disorders0/421/510/370/45
Most frequent other events
Showing 10 of 101
Most frequent other events
EventDouble-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgPlacebo to Open-label Oral Budesonide Suspension (OBS) 2 mgOral Budesonide Suspension (OBS) 2 mg to Open-label OBS 2 mg
NasopharyngitisInfections and infestations4/423/514/375/45
Oesophageal candidiasisInfections and infestations0/421/514/370/45
Upper respiratory tract infectionInfections and infestations2/423/514/373/45
Wrist fractureInjury, poisoning and procedural complications0/420/513/370/45
HeadacheNervous system disorders0/421/513/371/45
AsthmaRespiratory, thoracic and mediastinal disorders1/420/513/370/45
Vulvovaginal mycotic infectionInfections and infestations1/420/512/370/45
AcneSkin and subcutaneous tissue disorders0/421/512/370/45
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/422/510/371/45
DiarrhoeaGastrointestinal disorders1/421/510/372/45

Baseline characteristics

The Safety Analysis Set, defined as all randomized participants who received at least 1 dose of double-blind study drug (placebo or OBS); subjects were analyzed based on the actual treatment received.

Age, Continuous
Age, Continuous(years)Double-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgTotal
Mean20.8 ± 7.5022.3 ± 7.9221.6 ± 7.73
Age, Customized
Age, Customized(Participants)Double-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgTotal
<18 Years Of Age171835
>/= 18 Years Of Age253358
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind PlaceboDouble-blind Oral Budesonide Suspension (OBS) 2 mgTotal
Female131629
Male293564
08

Study locations

23 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • UCSD Rady Children's Hospital
    San Diego, California 92123, United States
  • The Children's Hospital
    Aurora, Colorado 80045, United States
  • Children's Center for Digestive Healthcare
    Atlanta, Georgia 30342, United States
  • Northwestern Scool of Medicine
    Chicago, Illinois 60611, United States
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • Center for Children's Digestive Health
    Park Ridge, Illinois 60068, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • The Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • The Cincinnati Center for Eosinophilic Disorders
    Cincinnati, Ohio 45229, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Children's Center for Digestive Health
    Greenville, South Carolina 29615, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Utah Healthcare
    Salt Lake City, Utah 84132, United States
  • Carilion Pediatric Gastroenterology
    Roanoke, Virginia 24013, United States
09

References and documents

Publications

  • Dellon ES, Collins MH, Katzka DA, Hudgens S, Lan L, Williams J, Vera-Llonch M, Hirano I. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. Clin Gastroenterol Hepatol. 2021 Apr;19(4):699-706.e4. doi: 10.1016/j.cgh.2020.03.060. Epub 2020 Apr 6. PubMed 32272243 ↗
  • Hirano I, Dellon ES, Collins MH, Williams J, Lan L, Katzka DA. Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2126-2128.e1. doi: 10.1016/j.cgh.2018.11.045. Epub 2018 Nov 28. PubMed 30502508 ↗
  • Dellon ES, Katzka DA, Collins MH, Gupta SK, Lan L, Williams J, Hirano I. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2019 Mar;17(4):666-673.e8. doi: 10.1016/j.cgh.2018.05.051. Epub 2018 Jun 12. PubMed 29902649 ↗
  • Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I; MP-101-06 Investigators. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. Gastroenterology. 2017 Mar;152(4):776-786.e5. doi: 10.1053/j.gastro.2016.11.021. Epub 2016 Nov 23. PubMed 27889574 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Oct 2014, 27 months.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2012
First posted
Jul 17, 2012
StartActual
Jul 23, 2012
Primary completionActual
Oct 30, 2014
CompletionActual
Oct 30, 2014
Results first posted
Dec 7, 2015
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01642212
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 17, 2012
Start date
Jul 23, 2012
Primary completion
Oct 30, 2014
Completion
Oct 30, 2014
Results posted
Dec 7, 2015
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion